This page is part of the Genetic Reporting Implementation Guide (v2.0.0: STU 2) based on FHIR R4. This is the current published version. For a full list of available versions, see the Directory of published versions
<Task xmlns="http://hl7.org/fhir">
<id value="PGxRecEx05"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative</b></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource "PGxRecEx05" </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-followup-recommendation.html">Followup Recommendation</a></p></div><p><b>status</b>: requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: Decrease dose <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="https://loinc.org/">LOINC</a>#LA26422-8)</span></p><p><b>description</b>: For amitriptyline, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for- tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.</p><p><b>for</b>: <a href="Patient-CGPatientExample01.html">Patient/CGPatientExample01</a> " EVERYMAN"</p><p><b>reasonReference</b>: <a href="Observation-TxImp05.html">Observation/TxImp05: Poor metabolizer</a></p></div>
</text>
<status value="requested"/>
<intent value="proposal"/>
<code>
<coding>
<system value="http://loinc.org"/>
<code value="LA26422-8"/>
<display value="Decrease dose"/>
</coding>
</code>
<description
value="For amitriptyline, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for- tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations."/>
<for>
<reference value="Patient/CGPatientExample01"/>
</for>
<reasonReference>
<reference value="Observation/TxImp05"/>
<display value="Poor metabolizer"/>
</reasonReference>
</Task>